Challenger Gold Ltd (CLLEF): Still under considerable accumulation -...

Still under considerable accumulation - we'll be headed

True Blue · 2008-07-01T22:06:04.8930000Z

Still under considerable accumulation - we'll be headed higher again shortly!

Play Episode

7min

Proactive - Interviews for investors

Mt York Gold: Kairos Minerals targets major growth

Kairos Minerals Ltd managing director Dr Peter Turner talked with Proactive about the company's Mt York Gold Project in Western Australia’s Pilbara region. Turner outlined why the company is enthusiastic about the asset, highlighting the 1.4 million ounce gold resource, which he said is largely hosted in a single open pit with clean metallurgy. “There's enormous upside in terms of the resource,” he said, pointing to ongoing technical work and a key land access deal with Pilbara Minerals as drivers for growth. He noted that the mineralisation is continuous over three kilometres and spans three key prospects: Main Hill, Breccia Hill, and Gossan Hill. Drilling along this corridor has consistently intersected gold, with further upside potential extending 1.5 kilometres onto neighbouring ground recently secured from Pilbara Minerals. Kairos is well funded, with A$12.4 million in the bank and a further A$10 million expected from its deal with Pilbara Minerals. These funds will support an extensive 20,000–30,000 metre drill program, targeting both resource growth and conversion of inferred resources to indicated. Turner said a priority focus is the Main Hill extension, with plans to conduct detailed diamond drilling and incorporate any new results into a future resource update. He also said that the company is entering a pivotal period: “We feel that 2025 is probably our kairos moment.” The year ahead will include new drill results, feasibility progress, and a resource update. Turner invited viewers to watch the company’s latest corporate video for a concise overview of Kairos’ strategy and current valuation. 👉 For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications for future updates. #KairosMinerals #MtYorkGoldProject #GoldExploration #PilbaraMining #ResourceGrowth #MiningInvestment #AustralianGold #JuniorMiners #DrillingUpdate #MiningNews #GoldStocks

Proactive - Interviews for investors

Brazil Potash’s Autazes Project fully permitted, poised for construction

Brazil Potash CEO Matt Simpson joined Steve Darling from Proactive providing key updates on the company’s Autazes Potash Project in northwest Brazil. The project has successfully completed all necessary permitting milestones—including technical, environmental, indigenous, and public consultations—clearing the way for full-scale construction. Brazil, which currently imports 98% of its potash, remains heavily reliant on foreign supply. The Autazes Project is designed to address this dependency by supplying 2.4 million tonnes annually, equivalent to approximately 17% of the country’s current potash demand, all of which will be sold domestically. Simpson highlighted the project's cost advantages, emphasizing that because production is based in Brazil, the total cost of extraction, processing, and delivery is lower than the transportation cost alone for imported potash. The construction of the Autazes Project will follow a modular approach, with major components pre-assembled offsite—including in Manaus—and then transported via the Madeira River to mitigate potential weather-related risks. This approach ensures greater efficiency, productivity, and quality control throughout the construction phase. Brazil Potash has already secured key commercial agreements to support project financing. The company has signed an offtake agreement with Amaggi, one of Brazil’s largest soybean producers, for 550,000 tonnes over 15 to 17 years and a MOU with Keytrade, a major global agribusiness player, for an additional one million tonnes. These agreements play a pivotal role in ongoing debt financing discussions with banks and export credit agencies, further de-risking the project for potential investors. Institutional support for Brazil Potash remains strong, with backing from Seed Capital (UK), Sentient Group (Australia), and Franco-Nevada. The latter recently invested $10 million after conducting extensive due diligence, further validating the project's viability. Looking ahead, Brazil

Proactive - Interviews for investors

Abacus Global Management CEO on 2024 highlights and 2025 targets

Abacus Global Management (NASDAQ:ABL) CEO Jay Jackson takes Proactive's Stephen Gunnion through the company’s strong financial performance in 2024 and its strategic outlook for 2025. The pioneering alternative asset manager reported 69% year-over-year revenue growth for 2024, with the fourth quarter alone seeing a 40% increase. Jackson noted that 2023 was already a record year, and 2024 surpassed that benchmark by over 50%. The company has issued guidance for 2025 that anticipates adjusted net income to rise by between 51% and 68%, driven by continued demand for non-correlated assets. Founded over 20 years ago, Abacus recently rebranded from Abacus Life to better reflect its identity as an alternative asset manager. Jackson explained, “We're an asset manager... and we also own a large institutional asset manager in Luxembourg,” underlining the firm’s expanding global footprint. Growth drivers include strategic acquisitions, expansion of its financial advisor channel, and development in its technology division. Jackson emphasized the role of AI in analyzing health and lifespan data to support financial planning, stating, “Think about the billion scenarios in someone's lifespan… AI helps us understand more accurate outcomes.” Jackson believes 2025 will bring increasing attention to the firm’s asset management operations, complementing its origination and technology capabilities. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications to stay updated. #AbacusGlobal #AlternativeAssets #JayJackson #AssetManagement #LifeInsuranceInvesting #AIinFinance #FinancialPlanning #SmallCapStocks #2025Outlook #InvestorInsights #NonCorrelatedAssets #TechInFinance

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Followers	29
Posts	5534
Boards Moderated	1
Alias Born	01/12/2006

Volume:	-
Day Range:
Bid:	0.0008
Ask:	472.05
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

CLLEF Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free